Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sugar-Tweaked heart hormone tested in healthy volunteers

NCT ID NCT07606183

Knowledge-focused Sponsor: Peter Fruergaard Andersen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study in 17 healthy male volunteers examines how a natural sugar modification on the heart hormone ANP changes its effects on blood pressure and fluid balance. Participants receive intravenous infusions of both the sugar-modified and unmodified forms of the hormone, plus a saline placebo, on separate days. The goal is to understand whether the sugar attachment alters how the hormone works, which could inform future treatments for conditions like heart failure and high blood pressure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
glycosylated atrial natriuretic peptide (gANP) and non-glycosylated ANP
What this could lead to
If successful, this could help researchers understand how a natural sugar modification changes the heart hormone's effects, potentially pointing toward new treatments for high blood pressure or heart failure.
What could go wrong
This is a very early, small study in only 17 healthy young men, not patients. The results may not apply to older or sicker people, and the hormone is given by IV, not as a pill.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

17 people

The number who actually took part.

Started

May 2022

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy male volunteers * Age: 18-30 years * BMI: 20-25 kg/m² * Body weight ≤90 kg (amended protocol) * Normal hemoglobin * Ability to provide informed consent Exclusion Criteria: * Acute illness within two weeks * Chronic cardiovascular, renal, hepatic, pulmonary, metabolic or malignant disease * Hypotension or history of syncope * Smoking * Substance or alcohol abuse * Recent blood donation (\<3 months) * Medication that cannot be safely interrupted

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation, familial, 6 heart failure hypertensive disorder kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Hypertension Kidney failure

Contacts and locations

Locations

  • 4) Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark

    Copenhagen, 2400, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.